

**Minutes of the March 21, 2014
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical Services**

Members Present

Richard Holm, MD; Michelle Baack, MD; Bill Ladwig, RPh; James Engelbrecht, MD; Kelly Oehlke, PharmD; Dana Darger, RPh

DSS staff present

Mike Jockheck, RPh; Kirby Stone, Director of Medical Services

Administrative Business

The P&T meeting was called to order by D. Darger at 1:00pm. The minutes of the December 6, 2013 meeting were presented. M. Baack made a motion to approve. J. Engelbrecht seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

The committee reviewed the prior authorization (PA) activity for January 2014. There were a total of 2,907 PA's processed in the month of January, with 99.86% of those requests responded to in less than eight hours. There were 2,312 (80%) requests received electronically and 595 (20%) requests received by fax.

Analysis of the top 15 Therapeutic Classes

The committee reviewed the Top 15 Therapeutic Classes by total cost of claims from 10/1/2013 – 12/31/2013. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, central nervous system agents, misc., and corticosteroids (respiratory tract). The top 15 therapeutic classes make up 40.51% of total claims. The Committee also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 10.61% of total claims. The committee requested that Advair utilization and stimulant usage in adults be added to the agenda for the June meeting.

Quantity Limit Review

The committee reviewed a list of quantity limit suggestions sorted by drug name. A motion was made by B. Ladwig to implement the quantity limits shown on the list. M. Baack seconded the motion. The motion was approved unanimously.

Brisdelle Second Review

The committee made a motion at the March meeting to place Brisdelle on prior authorization. The prior authorization form was provided for committee review. A motion was made by J. Engelbrecht to approve the form. M. Baack seconded the motion. There was no public comment. The motion was approved unanimously.

Sovaldi and Olysio Review

The committee reviewed Olysio and Sovaldi. The committee heard testimony from Michele Puyear (Gilead) and Kathleen Karnik (Janssen). A motion was made by B. Ladwig to place Sovaldi and Olysio on prior authorization using available guidelines. R. Holm seconded the motion. The motion was approved unanimously. Forms and criteria will be brought to the June meeting for committee review.

Luzu Review

The committee reviewed Luzu clinical information. There was no public comment. A motion was made by B. Ladwig to place Luzu on prior authorization. R. Holm seconded the motion. The motion was approved unanimously. A prior authorization form will be brought to the June meeting for committee review.

Hetlioz Review

The committee reviewed Hetlioz clinical information. There was no public comment. A motion was made by M. Baack to place Hetlioz on prior authorization. R. Holm seconded the motion. The motion was approved unanimously. A prior authorization form will be brought to the June meeting for committee review.

Prior Authorization Forms and Criteria Annual Review

The committee reviewed current prior authorization forms and criteria. Changes made include:

1. Antidepressant form – PA brand SSRIs only
2. Oracea/Solodyn form – remove tetracycline

J. Engelbrecht made a motion to make the listed changes to the prior authorization forms. R. Holm seconded the motion. The motion was approved unanimously.

The next meeting is scheduled for June 6, 2014. K. Oehlke made a motion to adjourn the P&T Committee meeting. J. Engelbrecht seconded the motion. The motion passed unanimously and the meeting was adjourned.